The study successfully met its primary endpoint, demonstrating similar rates of viral suppression for DOR/ISL compared to Biktarvy at 48 weeks
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
The formulation is backed by over 80 clinical trials and 200 scientific publications
The licence covers Actimed’s existing patents, its proprietary know-how and any future related patents, giving Mankind full control to advance the products under its own brands
The 2025 edition of the EdelGive Hurun list recognizes 24 exceptional women leaders for their philanthropic impact across critical areas
Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub
Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration
The move is expected to be crucial during health crises
Subscribe To Our Newsletter & Stay Updated